
Patient-Reported Outcomes Reinforce Clinical Benefits of Tarlatamab in Small Cell Lung Cancer
Tarlatamab (Imdelltra; Amgen) demonstrated moderate and long-lasting tolerability with a strong benefit-risk profile in previously treated small cell lung cancer (SCLC), with favorable patient-reported outcomes (PROs) across a spectrum of functional …